Extra-vascular modeling MCQs With Answer
Introduction: This quiz collection focuses on extravascular modeling — a core topic in Advanced Biopharmaceutics & Pharmacokinetics for M.Pharm students. It covers theoretical and applied aspects of drug absorption from non-intravenous routes, including first- and zero-order absorption, flip-flop kinetics, transit-compartment and deconvolution approaches, Wagner–Nelson and Loo–Riegelman methods, lag time, mean absorption time, and factors affecting oral bioavailability. Questions emphasize model selection, parameter interpretation, mathematical relationships (ka, ke, V/F, CL/F), and real-world formulation implications like dissolution- or permeability-limited absorption, enterohepatic recirculation, and controlled-release behavior. Use this set to test and deepen your mechanistic understanding and problem-solving skills in extravascular kinetics.
Q1. In a one-compartment extravascular model with first-order absorption, which primary assumption underlies the model?
- The absorption process is saturable and dose-dependent
- The drug distributes instantly and homogeneously into a single compartment while absorption follows first-order kinetics
- The elimination follows zero-order kinetics irrespective of concentration
- Bioavailability is always unity and independent of formulation
Correct Answer: The drug distributes instantly and homogeneously into a single compartment while absorption follows first-order kinetics
Q2. Flip-flop kinetics is observed when which condition holds true for the absorption (ka) and elimination (ke) rate constants?
- ka >> ke, so absorption is much faster than elimination
- ka ≈ ke, resulting in indistinguishable phases
- ka < ke, so absorption is slower than elimination and governs the terminal slope
- ka = 0, indicating no absorption
Correct Answer: ka < ke, so absorption is slower than elimination and governs the terminal slope
Q3. The Wagner–Nelson method is used to:
- Estimate the fraction of drug absorbed over time for a one-compartment model using plasma concentration and AUC data
- Separate distribution from elimination in a two-compartment model without IV data
- Directly compute absolute bioavailability without any IV reference
- Predict intestinal permeability from in vitro dissolution data
Correct Answer: Estimate the fraction of drug absorbed over time for a one-compartment model using plasma concentration and AUC data
Q4. The Loo–Riegelman method is particularly appropriate when:
- Analyzing one-compartment first-order absorption data without needing IV information
- Determining fraction absorbed for two-compartment disposition and requiring IV pharmacokinetic parameters
- Estimating mean absorption time from single-dose oral data in nonlinear kinetics
- Modeling controlled-release zero-order absorption exclusively
Correct Answer: Determining fraction absorbed for two-compartment disposition and requiring IV pharmacokinetic parameters
Q5. Mean absorption time (MAT) can be calculated as:
- The difference between Tmax and Cmax
- The difference between mean residence time after extravascular dosing (MRTpo) and MRT after IV dosing (MRTiv)
- The reciprocal of the absorption rate constant (1/ka) only
- The time at which 50% of the dose is absorbed
Correct Answer: The difference between mean residence time after extravascular dosing (MRTpo) and MRT after IV dosing (MRTiv)
Q6. Transit compartment models are useful because they:
- Assume instantaneous absorption without delay
- Represent absorption delay and variability by a chain of sequential transit compartments producing a gamma-like absorption profile
- Only model zero-order release kinetics from dosage forms
- Eliminate the need to estimate ka or lag time
Correct Answer: Represent absorption delay and variability by a chain of sequential transit compartments producing a gamma-like absorption profile
Q7. Zero-order absorption is characterized by which of the following?
- An absorption rate proportional to the remaining drug at the absorption site
- A constant absorption rate independent of drug concentration at the site, often seen with certain controlled-release systems
- An absorption rate that follows Michaelis–Menten saturation kinetics
- Immediate and complete absorption at time zero
Correct Answer: A constant absorption rate independent of drug concentration at the site, often seen with certain controlled-release systems
Q8. Oral bioavailability (F) can be mechanistically expressed as:
- F = Fraction metabolized in liver × Fraction metabolized in gut
- F = Fa × Fg × Fh, representing fraction absorbed, fraction escaping gut wall metabolism, and fraction escaping hepatic first-pass
- F = CL/V, where CL is clearance and V is volume of distribution
- F = ka/ke for first-order models
Correct Answer: F = Fa × Fg × Fh, representing fraction absorbed, fraction escaping gut wall metabolism, and fraction escaping hepatic first-pass
Q9. Deconvolution in extravascular modeling is primarily used to:
- Estimate elimination half-life without any IV reference
- Determine the in vivo absorption rate-time profile by using the known disposition (unit impulse response) and observed plasma concentrations
- Compute Cmax directly from dose and Vd
- Replace the need for noncompartmental analysis
Correct Answer: Determine the in vivo absorption rate-time profile by using the known disposition (unit impulse response) and observed plasma concentrations
Q10. For a first-order absorption and elimination model, Tmax behavior indicates that:
- Tmax is independent of both ka and ke
- Tmax = ln(ka/ke)/(ka − ke), therefore Tmax increases as ka decreases relative to ke
- Tmax always equals 1/ka
- Tmax is directly proportional to bioavailability
Correct Answer: Tmax = ln(ka/ke)/(ka − ke), therefore Tmax increases as ka decreases relative to ke
Q11. A characteristic cause of a double-peak concentration–time profile after oral dosing is most commonly:
- Saturable renal clearance at therapeutic concentrations
- Enterohepatic recirculation or secondary absorption due to biliary excretion
- Immediate intravenous contamination during oral administration
- First-pass hepatic extraction alone without any secondary release
Correct Answer: Enterohepatic recirculation or secondary absorption due to biliary excretion
Q12. Saturable intestinal uptake leading to nonlinear absorption is best described by which statement?
- Absorption rate increases linearly with dose at all concentrations
- At higher doses carrier-mediated transport may approach Vmax, so fractional absorption decreases and AUC increases less than proportionally
- Permeability always increases with dose
- First-pass metabolism becomes irrelevant in saturable absorption
Correct Answer: At higher doses carrier-mediated transport may approach Vmax, so fractional absorption decreases and AUC increases less than proportionally
Q13. After oral dosing, estimated pharmacokinetic volumes are often reported as V/F. What does this imply?
- V/F equals the true physiological volume of distribution, independent of bioavailability
- V/F is an apparent volume that conflates true V with unknown bioavailability, so absolute V cannot be determined without F
- V/F is only used for IV dosing and not for extravascular routes
- V/F indicates that distribution is instantaneous and independent of dose
Correct Answer: V/F is an apparent volume that conflates true V with unknown bioavailability, so absolute V cannot be determined without F
Q14. When absorption is permeability-limited (e.g., BCS class III), which strategy is least likely to improve systemic exposure?
- Increasing drug solubility in the gastrointestinal fluid
- Using permeation enhancers or transport modulators
- Formulating as nanoparticles to improve intestinal uptake
- Altering pH microenvironment to increase membrane permeation
Correct Answer: Increasing drug solubility in the gastrointestinal fluid
Q15. For a one-compartment model with first-order absorption and elimination, the plasma concentration-time equation after an oral dose is:
- C(t) = (F · Dose / V) · (e^{−ke·t} − e^{−ka·t})
- C(t) = (F · Dose · ka)/(V(ka − ke)) · (e^{−ke·t} − e^{−ka·t})
- C(t) = (Dose/V) · e^{−ka·t}
- C(t) = (F · Dose)/(CL) · (1 − e^{−ke·t})
Correct Answer: C(t) = (F · Dose · ka)/(V(ka − ke)) · (e^{−ke·t} − e^{−ka·t})
Q16. In deconvolution terminology, the “unit impulse response” refers to:
- The absorption profile after oral dosing normalized to dose
- The plasma concentration-time curve resulting from an instantaneous unit input (e.g., unit bolus) that characterizes disposition
- The dissolution profile of the dosage form in vitro
- The cumulative fraction excreted unchanged in urine
Correct Answer: The plasma concentration-time curve resulting from an instantaneous unit input (e.g., unit bolus) that characterizes disposition
Q17. A key assumption of the Wagner–Nelson approach is that:
- Pharmacokinetics are nonlinear and multi-compartmental
- The drug follows linear kinetics and a one-compartment disposition model with instantaneous distribution within that compartment
- Bioavailability changes with time during absorption
- Elimination is zero-order
Correct Answer: The drug follows linear kinetics and a one-compartment disposition model with instantaneous distribution within that compartment
Q18. When flip-flop kinetics exists but is not recognized, which PK parameter derived from oral data is most likely to be misinterpreted?
- Cmax, because it will always be overpredicted
- Apparent terminal half-life, because it will reflect the absorption rate rather than true elimination half-life
- Volume of distribution estimated from IV data
- Bioavailability, which becomes exactly equal to unity
Correct Answer: Apparent terminal half-life, because it will reflect the absorption rate rather than true elimination half-life
Q19. Increasing absorption lag time (Tlag) while keeping extent of absorption constant will most likely:
- Decrease AUC substantially because less drug is absorbed
- Shift Tmax to a later time and may reduce Cmax, but AUC remains essentially unchanged
- Increase bioavailability by bypassing first-pass metabolism
- Convert first-order absorption into zero-order absorption
Correct Answer: Shift Tmax to a later time and may reduce Cmax, but AUC remains essentially unchanged
Q20. For modeling complex controlled-release oral formulations that show delayed and multiple absorption peaks, the most flexible mechanistic approach is typically:
- Using a simple single-compartment first-order absorption model with no lag time
- Applying transit-compartment or multi-input convolution models to represent delays, variable release and multiple absorption events
- Always using Loo–Riegelman method regardless of compartmental behavior
- Relying solely on noncompartmental analysis to capture peak structure
Correct Answer: Applying transit-compartment or multi-input convolution models to represent delays, variable release and multiple absorption events
